PM's share price has broken above its 50‑day moving average, trading near $188 with a 1.5% weekly gain, while earnings per share continue to beat estimates, supporting a higher valuation multiple. With a healthy free‑cash‑flow yield (~5%) and strong FY23 profit growth, the fundamentals remain solid, justifying a bullish stance.

Investor sentiment stays upbeat as PM outperforms peers in the Q4 winners‑losers roundup, driven by robust reduced‑risk product sales. The narrative of oral nicotine as a growth catalyst further fuels positive market expectations, keeping the stock in bullish favor.

Regulatory risk persists, especially around oral nicotine approvals, but PM's diversified product pipeline and global market share mitigate long‑term downside. Given its track record of incremental revenue growth and strategic acquisitions, the long‑term outlook remains bullish.

Technical indicators show the 14‑day RSI at 58 and the price above both the 20‑day and 50‑day EMAs, suggesting upward momentum without overbought pressure. Volume has risen 22% week‑over‑week, confirming bullish volume patterns.